Last updated on June 2019

Community-Acquired Pneumonia : Evaluation of Corticosteroids


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Community Acquired Pneumonia
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Age 18 years
  • Patients affiliated to social security scheme
  • Admission to an Intensive Care Unit (ICU) or intermediate care unit participating to the trial
  • Diagnosis of Community- Acquired Pneumonia (CAP) suggested by at least two of the following: cough, purulent sputum, chest pain and dyspnea
  • Focal shadowing/infiltrate on chest X-ray or CT-scan
  • Diagnosis of Community- Acquired Pneumonia (CAP) during the 48 hours post-hospital admission
  • Study drug infusion initiated no longer than 24 hours post first severity criterion
  • Severity defined by at least one of the following:
  • Pneumonia Severity Index (PSI) > 130 (Fine class V)
  • Patient placed on mechanical ventilation (invasive or not) for acute respiratory failure, with a PEEP level of 5 cm of water or more
  • Patient treated by high-flow oxygen therapy with a FiO2 of 50% or more and a P/F ratio less than 300
  • Patient treated by oxygen therapy with a partial rebreathing-mask with a reservoir bag, provided that the PaO2 is less than (cf. table):

Oxygen flow (L/min) 6 7 8 9 10 or more PaO2 (mmHg) less than 180 210 240 270 300

  • Patient already treated by antibiotics (at least one dose since admission to hospital)
  • Informed consent signed by the patient, its relatives or emergency procedure

Exclusion Criteria:

  • Patient treated by vasopressors for septic shock at the time of inclusion
  • Clinical history suggesting of aspiration of gastric content
  • Patient treated by invasive mechanical ventilation within 14 days before current hospital admission
  • Patient treated by antibiotics for a respiratory infection for more than seven days at the admission to the hospital (except if a pathogen resistant to this antibiotics is isolated)
  • History of cystic fibrosis
  • Post-obstructive pneumonia
  • Patients in which rapid PCR-test is positive for flu
  • Active tuberculosis or fungal infection
  • Active viral hepatitis or active infection with herpes viruses
  • Myelosuppression
  • Decision of withholding mechanical ventilation or endotracheal intubation
  • Hypersensitivity to corticosteroids
  • Patient needing anti-inflammatory corticosteroids or substitutive hydrocortisone for any reason
  • Patients under treatment by more than 15 mg/d of prednisone (or equivalent) for more than 30 days
  • Patient already enrolled in another drug trial with mortality as an end-point. If the patient is already participating in another therapeutic trial with a different endpoint, the investigator must verify that inclusion in CAPE COD can not prejudice it.
  • Pregnant or breastfeeding woman
  • Patient on judicial protection

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.